Cannabis Review. Hazekamp, Arno.
Department of Plant Metabolomics, Leiden University, Leiden. The Netherlands. 2008-2009.

Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Oesch, Susanne, et al.
Molecular Cancer Therapeutics. July 2009; 8(7): 1838-1845.

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). Fraser, G A.
CNS Neuroscience & Therapeutics. 2009 Winter, 15(1): 84-88 (abstract).

Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. Ren, Yanhua, et al.
The Journal of Neuroscience. 2009 Nov 25, 29(47): 14764-14769.

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Izzo, Angelo A, et al.
Trends in Pharmacological Sciences. 2009 30(10) (abstract).

A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Liang, C, et al.
Cancer Prevention Research (Phila). 2009 Aug, 2(8): 756-768 (abstract).

Preventative and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation. Rogerio, Alexandre P, et al.
British Journal of Pharmacology. 2009 Oct, 15(4): 1074-1087.

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). Fraser, G A
CNS Neuroscience and Therapeutics. 2009 Winter 15(1): 84-88 (abstract).

ENTER YOUR EMAIL AND GET

10% OFF

YOUR NEXT ORDER

Be the first to learn about our new product additions, events and special promotions.